SKIN CANCERS

A patient with a high-risk skin cancer has been administered an investigational interleukin 7 agent, efineptakin alfa, plus atezolizumab, initiating treatment in a phase 2a study.

In an interview with Targeted Oncology, Michael A. Postow, MD, summarized the treatment landscape, provided takeaways from the most recent additions, and discussed other targets for metastatic melanoma.

Topline results from an international phase 1 study of cosibelimab are encouraging and may lead to the submission of a biologics license application to the FDA.

During a Targeted Oncology case-based roundtable event, Francis Paul Worden, MD, discussed treatment options for a patient with high-risk basal cell carcinoma.

Tebentafusp-tebn has been granted FDA approval to treat HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma based on positive results from a phase 3 study.

During a recent medical meeting, Michael Lowe, MD, MA, FACS, FSSO, and Ragini Kudchadkar, MD, debated adjuvant therapy versus neoadjuvant for the treatment of resectable stage III melanoma.

Efficacy was seen with blocking LAG-3 in combination with PD-1 as a therapeutic strategy for patients with melanoma. Additionally, this research establishes LAG-3 as the third immune checkpoint pathway to have proven clinical benefit in this patient population.

ST101 was granted a fast track designation based on preliminary data of an ongoing phase 1/2 trial.

Darovasertib and crizotinib demonstrated promising efficacy and tolerable safety in patients with metastatic uveal melanoma, according to preliminary results of a phase 1/2 trial announced in a press release from IDEAYA Biosciences.

The biopsy of a 88-year-man demonstrated infiltrative basal cell carcinoma. his case was the topic of discussion during a Case-Based Roundtable led by Nikhil I. Khushalani, MD.

Results from the EMPOWER-Cervical 1/ GOG-3016/ENGOT-cx9 trial led the FDA to grant priority review to cemiplimab as treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on or after chemotherapy.

An 88-year-old man presented with a nonhealing ulcer on the lateral aspect of his nose. The patient was diagnosed with Basal cell carcinoma.

The current standard of care for BCC is surgical excision. However, the procedure is often time consuming, expensive, and may lead to cosmetic and functional morbidity.

Meredith McKean, MD, MPH, moderated a Case-Based Roundtable discussion about a 88-year-old patient with Basel cell carcinoma.

Karl D. Lewis, MD, the professor of Medicine in the Cutaneous Oncology Program at University of Colorado in Aurora, CO, discussed the case of a 88-year-old patient with Basel cell carcinoma.

Cutaneous melanoma is disproportionately lethal among skin cancers, and as incidence rates of cutaneous melanoma continue to rise in the United States, so does the importance of managing melanoma cases in alignment with personalized prognoses.

According to Inge Marie Svane, MD, PhD, the truth about what drives tumor-infiltrating lymphocyte efficacy is not yet known, and more research is needed.

The FDA has expanded its approval for pembrolizumab monotherapy to include the treatment of patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

During a Targeted Oncology Case-Based Roundtable event, Michael K. Wong, MD, PhD, discussed the case of a 69-year-old patient with cutaneous squamous cell carcinoma.

Newer immunotherapy approaches continue to be explored to treat patients with relapsed or refractory MCC after PD-1/ PD-L1 inhibition.

Research has suggested that neoadjuvant immunotherapy combinations are superior to adjuvant immunotherapy for patients with stage III melanoma.

Targeted therapy use in melanoma has been extended beyond just metastatic disease to now include adjuvant therapy for patients with resected stage III melanoma.

The combination of alrizomadlin and pembrolizumab was well tolerated in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immuno-oncologic drugs treated in a phase 2 study.

In patients with pre-immune checkpoint inhibitor-naïve advanced melanoma, treatment with the combination of lifileucel plus pembrolizumab, compared to pembrolizumab alone, increased the overall response rate.

Novel methods of genetic testing have led to improved detection and better clinical decisions in patients with melanoma, especially in the late-stage setting.

The FDA has granted orphan drug designation to ITIL-168 for the treatment of stage IIB to IV melanoma, an investigational, autologous cell therapy derived from tumor-infiltrating lymphocytes.

Ezra Cohen, MD, lead a discussion on the efficacy of cemiplimab-rwlc for the treatment of cutaneous squamous cell carcinoma.

In the phase 2 C-144-01 trial, patients had durable responses to treatment with the tumor-infiltrating lymphocyte lifileucel after more than 28 months of follow-up.

In patient with metastatic uveal melanoma, frontline treatment with tebentafusp achieved significant and clinically meaningful improvement in overall survival, according to data from the phase 3 IMCgp100-202 trial.

Hedgehog inhibitors are becoming more widely used for Basal cell carcinoma. Two experts, Shailender Bhatia, MD and Paul T. Nghiem, MD, PhD discussed the reality of hedgehog inhibitor use in practice during a virtual Targeted Oncology Case-Based Roundtable event.